225 related articles for article (PubMed ID: 18166997)
1. Cardiac risks in multimodal breast cancer treatment.
Budach W
Strahlenther Onkol; 2007 Dec; 183 Spec No 2():9-10. PubMed ID: 18166997
[No Abstract] [Full Text] [Related]
2. [Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer].
Belkacémi Y; Laharie-Mineur H; Gligorov J; Azria D
Cancer Radiother; 2007 Sep; 11(5):266-75. PubMed ID: 17644449
[TBL] [Abstract][Full Text] [Related]
3. Tomorrow's targeted therapies in breast cancer patients: what is the risk for increased radiation-induced cardiac toxicity?
Magné N; Chargari C; MacDermed D; Conforti R; Védrine L; Spano JP; Khayat D
Crit Rev Oncol Hematol; 2010 Dec; 76(3):186-95. PubMed ID: 20138541
[TBL] [Abstract][Full Text] [Related]
4. Reversibility of trastuzumab cardiotoxicity: is the concept alive and well?
Ewer MS; Tan-Chiu E
J Clin Oncol; 2007 Dec; 25(34):5532-3; author reply 5533-4. PubMed ID: 18048835
[No Abstract] [Full Text] [Related]
5. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study.
Shaffer R; Tyldesley S; Rolles M; Chia S; Mohamed I
Radiother Oncol; 2009 Jan; 90(1):122-6. PubMed ID: 18976826
[TBL] [Abstract][Full Text] [Related]
6. [Cardioprotective treatment during adjuvant cancer therapy].
Gulati G; Heck SL; Ree AH; Gravdehaug B; Røsjø H; Steine K; Bratland Å; Hoffmann P; Geisler J; Omland T
Tidsskr Nor Laegeforen; 2013 Sep; 133(17):1832-6. PubMed ID: 24042297
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab cardio-oncology: lessons learned.
Frankel C
Clin J Oncol Nurs; 2010 Oct; 14(5):630-40. PubMed ID: 20880820
[TBL] [Abstract][Full Text] [Related]
9. Herceptin in early breast cancer: a call for judicious use.
Thorat MA
Natl Med J India; 2005; 18(6):315-7. PubMed ID: 16483033
[No Abstract] [Full Text] [Related]
10. Re: Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
Magné N; Chargari C
Nat Clin Pract Oncol; 2008 Nov; 5(11):E1. PubMed ID: 18957967
[No Abstract] [Full Text] [Related]
11. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
Gianni L; Salvatorelli E; Minotti G
Cardiovasc Toxicol; 2007; 7(2):67-71. PubMed ID: 17652806
[TBL] [Abstract][Full Text] [Related]
12. [Subclinical heart damage caused by adjuvant anthracycline chemotherapy].
Dunst J
Strahlenther Onkol; 2002 Feb; 178(2):110-1. PubMed ID: 11942035
[No Abstract] [Full Text] [Related]
13. Mixing anthracyclines and radiotherapy in early breast cancer: how safe is it?
HjiYiannakis P; Yarnold JR
Eur J Cancer; 1996 Oct; 32A(11):1845-8. PubMed ID: 8943665
[No Abstract] [Full Text] [Related]
14. Mixing anthracyclines and radiotherapy in early breast cancer: how safe is it?
HjiYiannakis P; Yarnold JR
Eur J Cancer; 1996 Dec; 32A(13):2374-7. PubMed ID: 9038631
[No Abstract] [Full Text] [Related]
15. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients.
Perik PJ; de Korte MA; van Veldhuisen DJ; Gietema JA; Sleijfer DT; de Vries EG
Expert Rev Anticancer Ther; 2007 Dec; 7(12):1763-71. PubMed ID: 18062750
[TBL] [Abstract][Full Text] [Related]
16. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials.
Bria E; Cuppone F; Fornier M; Nisticò C; Carlini P; Milella M; Sperduti I; Terzoli E; Cognetti F; Giannarelli D
Breast Cancer Res Treat; 2008 May; 109(2):231-9. PubMed ID: 17638068
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced cardiotoxicity in women.
Dempsey KS
Crit Care Nurs Clin North Am; 2008 Sep; 20(3):343-50. PubMed ID: 18644518
[TBL] [Abstract][Full Text] [Related]
18. [Difficulties in echocardiographic monitoring of trastuzumab therapy in breast cancer patients: case report and review of recommendations].
Duchnowska R; Szmit S; Szczylik C; Opolski G
Kardiol Pol; 2008 Aug; 66(8):895-8. PubMed ID: 18803144
[No Abstract] [Full Text] [Related]
19. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?
Morris PG; Hudis CA
J Clin Oncol; 2010 Jul; 28(21):3407-10. PubMed ID: 20530269
[No Abstract] [Full Text] [Related]
20. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
Telli ML; Hunt SA; Carlson RW; Guardino AE
J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
